Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Ernexa Therapeutics, a Nasdaq-listed biotechnology company, participated in a virtual investor conference to present its transition towards a clinical-stage company with its lead cell therapy candidate ERNA-101 advancing toward IND submission and an upcoming Phase 1 clinical trial. The company emphasized its innovative off-the-shelf iMSC platform t…